Product Description
Mechanisms of Action: 5-HT2A Inverse Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Greenleaf Jia'ao Pharmaceutical Shijiazhuang Co., Ltd.
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 11
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Alzheimer Disease|Hallucinations|Parkinson's Disease|Psychotic Disorders|Schizophrenia|Symptoms of Alzheimer Disease
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06793995 |
LY03017/CT-CHN-102 | P1 |
Not yet recruiting |
Symptoms of Alzheimer Disease|Parkinson's Disease|Schizophrenia|Psychotic Disorders|Alzheimer Disease |
2025-10-31 |
2025-01-28 |
Primary Endpoints |
|
NCT06980207 |
LY03017/CT-CHN-103 | P1 |
Not yet recruiting |
Alzheimer Disease|Symptoms of Alzheimer Disease|Schizophrenia|Parkinson's Disease|Psychotic Disorders|Hallucinations |
2025-10-01 |
2025-05-21 |
Primary Endpoints |
|
CTR20251723 |
CTR20251723 | P1 |
Completed |
Schizophrenia|Hallucinations|Symptoms of Alzheimer Disease|Alzheimer Disease |
2025-10-12 |
2026-09-16 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
CTR20251725 |
CTR20251725 | P1 |
Completed |
Parkinson's Disease|Schizophrenia|Hallucinations |
2025-10-12 |
2026-09-09 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
CTR20251724 |
CTR20251724 | P1 |
Completed |
Schizophrenia |
2025-10-12 |
2026-09-27 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
CTR20250131 |
CTR20250131 | P1 |
Completed |
Hallucinations|Parkinson's Disease|Schizophrenia |
2025-05-09 |
2026-09-16 |
Patient Enrollment|Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
CTR20250130 |
CTR20250130 | P1 |
Completed |
Schizophrenia|Hallucinations|Symptoms of Alzheimer Disease|Alzheimer Disease |
2025-05-09 |
2026-09-09 |
||
CTR20250132 |
CTR20250132 | P1 |
Completed |
Schizophrenia |
2025-05-09 |
2026-09-16 |
Patient Enrollment|Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
CTR20241354 |
CTR20241354 | P1 |
Completed |
Schizophrenia|Parkinson's Disease|Hallucinations |
2025-01-07 |
2026-09-09 |
Patient Enrollment|Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
CTR20241355 |
CTR20241355 | P1 |
Completed |
Hallucinations|Alzheimer Disease|Symptoms of Alzheimer Disease|Schizophrenia |
2025-01-07 |
2026-09-09 |
Patient Enrollment|Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
CTR20241353 |
CTR20241353 | P1 |
Completed |
Schizophrenia |
2025-01-07 |
2026-09-09 |
Patient Enrollment|Primary Completion Date|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|